Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).

• Suresh S Ramalingam, Glenwood D Goss, +19 authors D. A. Fennell
• Annals of oncology : official journal of the…
• 2015

BACKGROUND This trial was designed to evaluate the activity and safety of ganetespib in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) and to identify patient populations… (More)

Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.

• Djuro Macut, Konstantinos Tziomalos, +5 authors Dimitrios K Panidis
• Human reproduction
• 2016

STUDY QUESTION What are the most relevant factors associated with non-alcoholic fatty liver disease (NAFLD) in women with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER Insulin resistance (IR)… (More)

Multivariate analysis of prognostic factors in male breast cancer in Serbia.

• Sandra Branko Sipetic-Grujicic, Zafir Hajdar Murtezani, +6 authors Jadranka Milutin Maksimovic
• Asian Pacific journal of cancer prevention…
• 2014

BACKGROUND The aim of this study was to analyze the demographic and clinical characteristics of male breast cancer patients in Serbia, and furthermore to determine overall survival and predictive… (More)

A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).

• Glenwood D Goss, Zoran Gojko Andric, +16 authors D. A. Fennell
• 2013

CRA8007 Background: Heat shock protein 90 chaperone function is critical for the biological effects of several oncoproteins. Ganetespib (G) is a highly potent 2nd-generation Hsp90 inhibitor with a… (More)

Predictors of Subclinical Cardiovascular Disease in Women with Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and Arterial Blood Pressure

• Djuro Macut, Marina Bačević, +8 authors Tijana Šukilović
• International journal of endocrinology
• 2015

Background. Women with polycystic ovary syndrome (PCOS) could develop subclinical atherosclerosis during life. Purpose. To analyze cardiovascular risk (CVR) factors and their relation to clinical… (More)

Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.

• Lee S Schwartzberg, E J Roeland, +7 authors Meinolf Karthaus
• Annals of oncology : official journal of the…
• 2018

Background NEPA, an oral fixed combination of the NK1RA netupitant (300 mg) and clinically/pharmacologically distinct 5-HT3RA palonosetron (PALO, 0.50 mg), is the first fixed antiemetic combination… (More)

• ‹
• 1
• ›